[go: up one dir, main page]

HRP20171824T1 - (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A - Google Patents

(TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A Download PDF

Info

Publication number
HRP20171824T1
HRP20171824T1 HRP20171824TT HRP20171824T HRP20171824T1 HR P20171824 T1 HRP20171824 T1 HR P20171824T1 HR P20171824T T HRP20171824T T HR P20171824TT HR P20171824 T HRP20171824 T HR P20171824T HR P20171824 T1 HRP20171824 T1 HR P20171824T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
tieno
benzoxazepin
Prior art date
Application number
HRP20171824TT
Other languages
English (en)
Inventor
Andrew James Ledgard
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20171824T1 publication Critical patent/HRP20171824T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (9)

1. Spoj formule [image] , ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je HCl sol.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je tosilatna sol.
4. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu farmaceutski prihvatljivu sol, u kombinaciji s najmanje jednom farmaceutski prihvatljivom podlogom, razrjeđivačem ili pomoćnom tvari.
5. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
6. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju nesanice.
7. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 6, ili njegova farmaceutski prihvatljiva sol, naznačen time što je za nesanicu karakterističan otežani početak spavanja ili održavanje spavanja ili oboje.
8. Spoj, naznačen time što je namijenjen upotrebi u skladu s bilo patentnim zahtjevom 6 ili 7 kod čovjeka.
9. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu farmaceutski prihvatljivu sol, u kombinaciji s najmanje jednom farmaceutski prihvatljivom podlogom, pomoćnom tvari ili razrjeđivačem, te selektivnim inhibitorom povratnog unosa serotonin.
HRP20171824TT 2011-08-30 2012-08-22 (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A HRP20171824T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161528893P 2011-08-30 2011-08-30
PCT/US2012/051833 WO2013032804A1 (en) 2011-08-30 2012-08-22 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS
EP12756856.6A EP2751115B1 (en) 2011-08-30 2012-08-22 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

Publications (1)

Publication Number Publication Date
HRP20171824T1 true HRP20171824T1 (hr) 2017-12-29

Family

ID=46829875

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171824TT HRP20171824T1 (hr) 2011-08-30 2012-08-22 (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A

Country Status (22)

Country Link
US (1) US9512140B2 (hr)
EP (1) EP2751115B1 (hr)
JP (1) JP6042436B2 (hr)
KR (1) KR101596607B1 (hr)
CN (1) CN103958523B (hr)
AU (1) AU2012300451B2 (hr)
BR (1) BR112014004557A2 (hr)
CA (1) CA2843514C (hr)
DK (1) DK2751115T3 (hr)
EA (1) EA024248B1 (hr)
ES (1) ES2650225T3 (hr)
HR (1) HRP20171824T1 (hr)
HU (1) HUE034845T2 (hr)
LT (1) LT2751115T (hr)
MX (1) MX350419B (hr)
NO (1) NO2776955T3 (hr)
PL (1) PL2751115T3 (hr)
PT (1) PT2751115T (hr)
RS (1) RS56537B1 (hr)
SI (1) SI2751115T1 (hr)
WO (1) WO2013032804A1 (hr)
ZA (1) ZA201400874B (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012283035B2 (en) * 2011-07-08 2015-07-30 Eli Lilly & Company (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity H1 inverse agonists/5-HT2A antagonists
PL2943498T3 (pl) 2013-01-14 2018-01-31 Lilly Co Eli Związki (tieno[2,3-b][1,5]benzoksazepin-4-ylo)piperazyn-1-ylowe jako odwrotni agoniści h1 / antagoniści 5-ht2a o podwójnej aktywności
TW201625644A (zh) 2014-04-29 2016-07-16 美國禮來大藥廠 作為選擇性5-HTA反向促效劑之(噻吩并[2,3-b][1,5]苯并氧氮呯-4-基)哌嗪-1-基化合物
WO2018177993A1 (de) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Pyrazole zur bekämpfung von arthropoden
WO2018234488A1 (en) 2017-06-23 2018-12-27 Basf Se Substituted cyclopropyl derivatives
WO2019185413A1 (en) 2018-03-27 2019-10-03 Basf Se Pesticidal substituted cyclopropyl derivatives
PL3898602T3 (pl) 2018-12-21 2023-10-23 Ogeda N.V. Synteza 3-metylo-1,2,4-tiadiazolo-5-karbohydrazydu lub jego metylo-d3 deuterowanej postaci
MX2022004736A (es) * 2019-10-21 2022-07-27 Alairion Inc Derivados de acido 3-(4-(11h-dibenzo [b, e] [1, 4] azepin-6-il)piperazin-1-il)- y 3-(4- dibenzo [b, f] [1, 4] oxazepin/tiazepin/diazepin-11-il)piperazin-1-il)propanoico como moduladores de los receptores h1 y 5-ht2a para el tratamiento de los trastornos del sue?o.
EP4043444A1 (en) 2021-02-11 2022-08-17 Basf Se Substituted isoxazoline derivatives
IL304983A (en) 2021-02-11 2023-10-01 Basf Se Isoxazoline histories are transmuted
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7395251B2 (en) * 2005-07-01 2008-07-01 International Business Machines Corporation Neural networks for prediction and control
US7807828B2 (en) * 2005-08-11 2010-10-05 Hypnion, Inc. Olanzapine analogs and methods of use thereof

Also Published As

Publication number Publication date
EA024248B1 (ru) 2016-08-31
RS56537B1 (sr) 2018-02-28
BR112014004557A2 (pt) 2017-05-30
DK2751115T3 (en) 2017-10-23
US20140171411A1 (en) 2014-06-19
EP2751115A1 (en) 2014-07-09
CN103958523B (zh) 2016-07-27
HUE034845T2 (en) 2018-03-28
AU2012300451B2 (en) 2016-10-13
SI2751115T1 (sl) 2017-11-30
EP2751115B1 (en) 2017-09-20
JP2014525440A (ja) 2014-09-29
MX2014002473A (es) 2016-09-26
JP6042436B2 (ja) 2016-12-14
CN103958523A (zh) 2014-07-30
MX350419B (es) 2017-09-05
WO2013032804A1 (en) 2013-03-07
CA2843514C (en) 2017-01-10
ES2650225T3 (es) 2018-01-17
LT2751115T (lt) 2017-12-27
AU2012300451A1 (en) 2014-01-30
PT2751115T (pt) 2017-12-20
KR20140051355A (ko) 2014-04-30
ZA201400874B (en) 2015-10-28
CA2843514A1 (en) 2013-03-07
EA201490332A1 (ru) 2014-06-30
KR101596607B1 (ko) 2016-02-22
NO2776955T3 (hr) 2018-06-02
PL2751115T3 (pl) 2018-02-28
US9512140B2 (en) 2016-12-06

Similar Documents

Publication Publication Date Title
HRP20171824T1 (hr) (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A
HRP20171512T1 (hr) Derivati betulina
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
ME02910B (me) Spojevi tetrahidropirolotiazina
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
HRP20220766T1 (hr) Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
HRP20201949T1 (hr) 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
ME02400B (me) Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
MD20140084A2 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX394360B (es) Inhibidores de jak2 y alk2 y metodos para su uso.
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
ME02840B (me) Spojevi fenoksietilpiperidina
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
MX383762B (es) Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.
WO2014093583A3 (en) Synthetic methods for preparing 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, other salt forms of this compound and intermediates thereof
AR092960A1 (es) Procedimiento para preparar compuestos tienopirimidina
ME02405B (me) Spojevi pirazola као inhibitori sglt1
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
RU2019104946A (ru) Применение производного хромона в качестве антагониста дофаминового рецептора d3 для лечения расстройства аутистического спектра